Table 1. Clinicopathological analyses of the differentially expressed ADAR1 of 83 primary hepatocellular carcinoma patients.
| Variables |
ADAR |
P-value | ||
|---|---|---|---|---|
| Negative | Positive | |||
| Age, yearsa | ≤60 | 12 (75.0) | 55 (82.1) | 0.498 |
| >60 | 4 (25.0) | 12 (17.9) | ||
| Gendera | Female | 2 (12.5) | 16 (23.9) | 0.503 |
| Male | 14 (87.5) | 51 (76.1) | ||
| HBVa | No | 3 (18.8) | 11 (16.4) | 1.000 |
| Yes | 13 (81.3) | 56 (83.6) | ||
| Cirrhosis | No | 7 (43.8) | 33 (49.3) | 0.692 |
| Yes | 9 (56.3) | 34 (50.7) | ||
| AFP, ng/ml | ≤400 | 10 (62.5) | 42 (62.7) | 0.989 |
| >400 | 6 (37.5) | 25 (37.3) | ||
| Tumor size, cm | ≤5 | 8 (50.0) | 43 (64.2) | 0.295 |
| >5 | 8 (50.0) | 24 (35.8) | ||
| Recurrence | No | 10 (62.5) | 27 (40.3) | 0.108 |
| Yes | 6 (37.5) | 40 (59.7) | ||
Abbreviations: ADAR1, adenosine deaminases that act on RNA; AFP, α-fetoprotein; HbsAg, hepatitis B surface antigen
Negative means ADAR1 IHC scored as –,whereas positive scored as +, ++ or +++
a
Fisher’s exact test was used